07 May 2013 by Hotzone Solutions 0
French Fire Fighters Trained With Hotzone Solutions’ New Generation of Chemical Warfare Agent Simulants
Honeywell Acquires RAE Systems, A Global Gas Detection Company
06 May 2013 by Emergent BioSolutions, Inc. 0
Emergent BioSolutions Inc. announced that it has entered into an asset purchase agreement to acquire the Healthcare Protective Products Division (HPPD) of Bracco Diagnostics Inc.
06 May 2013 by S Johnson 0
Just a quick note for now - Carla Del Ponte, part of one of many investigations in to Syria, and not as was claimed by some press the head of the CW investigation (who is in fact Ake Sellstrom - an extremely competent investigator, who would not have made such a ridiculous statement), has made the headlines with her claims that Syrian Rebels have used Sarin gas and there is no evidence of state use.
The UN appears equally surprised and issued a terse statement:
“Geneva, 6 May 2013—The Independent International Commission of Inquiry on the Syrian Arab Republic wishes to clarify that it has not reached conclusive findings as to the use of chemical weapons in Syria by any parties to the conflict. As a result, the Commission is not in a position to further comment on the allegations at this time.
The Chair of the Commission of Inquiry, Paulo Sergio Pinheiro, reminds all parties to the conflict that the use of chemical weapons is prohibited in all circumstances under customary international humanitarian law.”
Del Ponte was basing her view off apparent reports from investigations and interviews in neighbouring countries. The sum total of her evidence? Some witness statements. Well that’s nice and reliable.
Really not what we need at the moment, and frankly calls her position in to serious question. If her judgement is so out of kilter on what will be a key aspect of Syrian investigations she should be replaced with someone less prone to making unsubstantiated claims that have huge repercussions and potential for causing international interventions.
The U.S. Army Materiel Systems Analysis Activity (USAMSSA), in conjunction with the Joint Requirements Office for Chemical, Biological, Radiological, and Nuclear Defense (JRO-CBRND), is seeking information on products, technologies, and approaches that support the mass casualty/patient decontamination of individuals who have been injured or are experiencing symptoms, from exposure to traditional chemical warfare agents, biological warfare agents, non-traditional agents, toxic industrial materials and radiological particles.
Although the focus is on products and/or technologies at Technology Readiness Level (TRL) 4 (as listed by the Chemical Biological Defense Program (CBDP) Technology Transition Handbook; 20 July 2005), we will consider technologies at lower TRLs if appropriate.
Specific information requested on each of the products or technologies includes:
Chemical, Biological, and Radiological Test Data to include efficacy, ability to contain agent contamination, and permeability resistivity)
Material Compatibility to include decontamination solutions including but not limited to caustic 1 to 18%, HTH, and bleach
Detector Compatibility (i.e., are there any known interferences with monitoring technologies?)
01 May 2013 by PathSensors, Inc. 0
PathSensors, Inc.specializes in technology that can monitor, detect and identify the toxin RICIN in 3 minutes or less.
01 May 2013 by S Johnson 0
Despite the effects of budget cuts in the US they still press on at the forefront of CBRN research and procurement with the evolution of a request for proposals and draft specifications for their Next Generation Chemical Detector (NGCD) program. Planned for release in 3rd quarter 2013 it plans to award contracts to multiple vendors for system prototypes.
Although this phase if for technology development it will see procurement in 2016 for what will be one of the largest CBRN contracts, certainly for chemical detection, in the world.
The question other countries must ask is if they don’t bring forward their own activities will they end up only having the option of variants of US research as their own procurement options?
Further details here